Moderna (NASDAQ: MRNA) is expected to post an EPS of $2.24 by the analysts for this ongoing financial year on 6th May, Thursday. The estimate for Moderna is ranging between $1.95 and $2.84. The company had $0.35 EPS last year this quarter, indicating a 740% annualized growth rate.
On Thursday, the company started from $129.75 with the market cap being $51.87 billion. Their lowest in 52 weeks is $19.31 while the highest is $189.26. Their current, quick, and leverage ratio is 2.43, 2.43, and 0.04. Their 50 day rolling average is $157.84 while the 200 day is $110.11.
According to their 25th February report, their quarterly revenue was $0.69, missing the $0.25 consensus estimate by almost $0.44. They had a 242.73% net negative margin with a 28.11% negative equity return. Their revenue was $570.80 million, surpassing the $279.41 million estimate.
MRNA Stock Has Consensus ‘Buy’ Recommendation
Argus raised the price objective for MRNA shares to $200 from $88 and gave a rating of ‘buy’. Jefferies Group upped it to $180 from $150 while Bank of America reassigned the rating of ‘sell’ with $140. Brookline Cap. Management raised it to $205 from $180 and gave a rating of ‘buy’. Morgan Stanley lowered it to $201 from $215 and gave a rating of ‘equal weight’. The company has the consensus ‘hold’ recommendation with a $150.56 price objective.
Stephen Hoge, the President, sold off 5,000 MRNA shares at $185 EPS worth $925,000. Stephane Bancel, the CEO, sold off 11,046 MRNA shares at $159.18 EPS worth $1,758,302.28. Insiders own 29.20% Moderna stock.
SOA Advisors bought new holdings in Moderna stock and own $73,000 worth of shares. Amundi Management raised their stake by roughly 2.6% and own shares priced at $50,941,000. B. Metzler Holding acquired a new position and own $442,000 worth of shares. Harvest Management bought a new stake, owning shares priced at $555,000. Institutional investors own 51.21% MRNA stock.
Moderna is one of the largest medical biotechnology companies. They have also been one of the companies to
